Menu Search
Equities

Poseida Therapeutics Inc

2RZ:DUS

Poseida Therapeutics Inc

Actions
  • Price (EUR)2.60
  • Today's Change-0.002 / -0.08%
  • Shares traded350.00
  • 1 Year change+4.08%
  • Beta--
Data delayed at least 15 minutes, as of May 03 2024 11:30 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Poseida Therapeutics, Inc. is a clinical-stage biopharmaceutical company advancing differentiated cell and gene therapies with the capacity to cure certain cancers and rare diseases. Its pipeline includes allogeneic CAR-T cell therapy product candidates for both solid and liquid tumors, as well as in vivo gene therapy product candidates that address patient populations with high unmet medical need. Its approach to cell and gene therapies is based on its proprietary genetic editing platforms, including its non-viral piggyBac DNA Delivery System, Cas-CLOVER Site-Specific Gene Editing System, Booster Molecule and nanoparticle and hybrid gene delivery technologies, as well as in-house GMP cell therapy manufacturing. Its lead programs, including P-FVIII-101, a non-viral approach. Its product candidate P-BCMA-ALLO1 and P-BCMACD19-ALLO1 is developed for patients with multiple myeloma. P-BCMA-ALLO1 is in a Phase I trial, being developed for patients with relapsed/refractory multiple myeloma.

  • Revenue in USD (TTM)64.70m
  • Net income in USD-123.43m
  • Incorporated2014
  • Employees330.00
  • Location
    Poseida Therapeutics Inc9390 TOWNE CENTRE DRIVE, SUITE 200SAN DIEGO 92121United StatesUSA
  • Phone+1 (858) 779-3100
  • Fax+1 (302) 636-5454
  • Websitehttps://poseida.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.